Journal Pre-proof



Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence

Kiran Shabir, James E. Brown, Islam Afzal, Seley Gharanei, Martin O. Weickert, Thomas M. Barber, Ioannis Kyrou, Harpal S. Randeva

PII: S1359-6101(21)00043-5

DOI: https://doi.org/10.1016/j.cytogfr.2021.05.002

Reference: CGFR 1229

To appear in: *Cytokine and Growth Factor Reviews*

Received Date: 8 April 2021

Revised Date: 9 May 2021

Accepted Date: 24 May 2021

Please cite this article as: { doi: https://doi.org/

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

Journal Pre-proof

Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: comprehensive review of preclinical and clinical evidence

Kiran Shabir[a,b], James E. Brown[b,c], Islam Afzal[c], Seley Gharanei[a,d], Martin O. Weickert[a,d,e], Thomas M. Barber[a,d], Ioannis Kyrou[a,b,d,f]*, Harpal S. Randeva[a,b,d]*

[a] Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, United Kingdom

[b] Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham, B4 7ET, United Kingdom

[c] School of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, B4 7ET, United Kingdom

[d] Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United Kingdom

[e] Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, CV1 5FB, United Kingdom

[f] Centre for Sport, Exercise and Life Sciences, Research Institute for Health & Wellbeing, Coventry University, CV1 5FB, United Kingdom

* Joint senior and corresponding authors; contributed equally to the manuscript.

Dr. Ioannis Kyrou: kyrouj@gmail.com

Prof. Harpal S. Randeva: harpal.randeva@uhcw.nhs.uk

Graphical abstract

Journal Pre-proof

Highlights

- Asprosin is a recently discovered pleiotropic adipokine that is released in response to fasting.
- Asprosin acts via an olfactory G-protein coupled receptor and potentially via other unknown receptor(s).
- Asprosin acts on hepatocytes to stimulate glucose release from the liver.
- Asprosin acts on orexigenic AgRP-expressing neurons in the hypothalamus to promote appetite.
- Circulating asprosin levels are increased in multiple cardio-metabolic diseases.

Abstract

White adipose tissue is a dynamic endocrine organ that releases an array of adipokines, which play a key role in regulating metabolic homeostasis and multiple other physiological processes. An altered adipokine secretion profile from adipose tissue depots frequently characterizes obesity and related cardio-metabolic diseases. Asprosin is a recently discovered adipokine that is released in response to fasting. Following secretion, asprosin acts - via an olfactory G-protein coupled receptor and potentially via other unknown receptor(s) - on hepatocytes and agouti-related peptide-expressing

Journal Pre-proof

Journal Pre-proof

neurons in the central nervous system to stimulate glucose secretion and promote appetite, respectively. A growing body of both *in vitro* and *in vivo* studies have shown asprosin to exert a number of effects on different metabolic tissues. Indeed, asprosin can attenuate insulin signalling and promote insulin resistance in skeletal muscle by increasing inflammation and endoplasmic reticulum stress. Interestingly, asprosin may also play a protective role in cardiomyocytes that are exposed to hypoxic conditions. Moreover, clinical studies have reported elevated circulating asprosin levels in obesity, type 2 diabetes and other obesity-related cardio-metabolic diseases, with significant associations to clinically relevant parameters. Understanding the spectrum of the effects of this novel adipokine is essential in order to determine its physiologic role and its significance as a potential therapeutic target and/or a biomarker of cardio-metabolic disease. The present review offers a comprehensive overview of the published literature on asprosin, including both clinical and preclinical studies, focusing on its role in metabolism and cardio-metabolic disease.

Keywords: adipokines, adipose tissue, asprosin, diabetes, inflammation, metabolism, obesity

1. Introduction

Over the past half century, obesity has become one of the most prevalent chronic, non-communicable diseases worldwide [1,2]. This marked increase in global obesity prevalence is attributed to a number of factors which collectively promote an obesogenic lifestyle and broader environment, including lifestyle Westernisation (*e.g.* energy/fat-rich diet and sedentary lifestyle), socio-economic determinants (*e.g.* urbanization, low socio-economic status and deprivation), and changes in food processing and marketing (*e.g.* processed red meat and aggressive marketing of sugar-sweetened

Journal Pre-proof

Journal Pre-proof

drinks) [1,3]. These factors facilitate the accumulation of excess adipose tissue due to a chronic positive balance between energy intake and energy expenditure, resulting in developing and sustaining obesity over time (often from a young age) [1,3]. It is now well-established that the pathophysiologic changes of adipose tissue in the course of obesity promote the development of the cardio-metabolic complications which characterize chronic obesity and are frequently manifested as a constellation in the context of the metabolic syndrome [4].

Indeed, adipose tissue is now considered a vital, dynamic endocrine organ and not just a passive storage depot of excess energy [4,5]. This endocrine function of adipose tissue is mediated by a broad range of adipose-derived factors (*i.e.* adipokines), which are directly or indirectly implicated in the regulation of multiple physiological processes, including energy homeostasis and appetite, as well as immune and cardio-metabolic functions (*e.g.* regulation of blood pressure) [6,7]. The number of identified adipokines has been rapidly increasing during the past two decades [8,9], and a growing body of *in vitro*, *in vivo* and clinical data indicate that these factors play distinct roles in the pathophysiology of obesity-related cardio-metabolic diseases [10,11]. Asprosin represents one of the recently identified adipokines [12], with emerging data suggesting that it may exert various effects implicated in a number of cardio-metabolic diseases, including type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and heart disease. As such, the present review focuses on this novel adipokine and offers a comprehensive overview of the available evidence on the effects of asprosin in metabolism and inflammation, including both preclinical and clinical data.

2. Fibrillin 1 (*FBN1*) gene and asprosin

Asprosin is produced together with fibrillin-1 (a large, extracellular matrix glycoprotein) by furin-mediated c-terminal cleavage of the pro-protein (profibrillin) encoded by the *Fibrillin 1 (FBN1)* gene (Figure 1) [12,13]. Indeed, the amino acid sequence of asprosin is encoded by the last two exons of

Journal Pre-proof

FBN1, namely exon 65 and 66 [12]. Mammalian asprosin is approximately 30 kDa and consists of 140 amino acids. Interestingly, a recent study that was able to form a strain of *Pichia pastoris* which expresses asprosin showed three glycosylation sites (threonine 8, 9 and 10) in two amino acid sequences of asprosin [14].

Asprosin was first described by Romere *et al*. (2016) [12] who investigated the sequencing of genomic DNA of patients with neonatal progeroid syndrome (NPS) and reported that mutations at the 3' end of the *FBN1* gene were present in two of these patients. These mutations translated to a truncated form of profibrillin [12], and were in accord to similar mutations in the *FBN1* gene of patients with NPS that had been previously reported by other studies [15–18]. Romere *et al.* (2016) [12] confirmed that these mutations were around the c-terminal cleavage site, resulting in the absence of asprosin. As such, these patients with NPS had significantly reduced circulating levels of asprosin compared to control subjects [12].

In both humans and mice, the highest *FBN1* expression is observed in the white adipose tissue, as well as in the lungs and heart [12]. Although *FBN1* expression has been shown to decrease during adipocyte differentiation, asprosin is readily secreted by mature adipocytes, thus representing an adipokine [12,13,19]. Accordingly, genetic ablation of adipose tissue in mice resulted in significantly decreased circulating asprosin levels compared to wild-type mice [12]. Notably, patients with NPS lack subcutaneous adipose tissue, which contributes to appearing older [17,18], and may also explain the low levels of circulating asprosin in these patients.

3. Glucogenic and orexigenic effects of asprosin

Asprosin acts directly on the liver, as well as on appetite-regulating neurons of the brain [12,20]. To date, asprosin has been shown to strongly bind to the membrane of hepatocytes and promote glucose production via a cyclic-AMP (cAMP)-protein kinase A (PKA) pathway [12]. Indeed, in the initial study by Romere *et al.* (2016) [12], asprosin was reported to elicit its effects through a G-protein

Journal Pre-proof

coupled receptor (GPCR), which was later identified as the olfactory receptor OLFR734 in mice [21]. *Olfr734* mRNA is highly expressed in the olfactory epithelium and olfactory bulb, as well as in the liver, kidneys and testes of mice. Using a liver-specific *Olfr734*-knockdown mouse model, Li *et al.* (2019) [22] showed that asprosin treatment significantly reduces the hepatic expression of gluconeogenic genes and the circulating glucose levels in these knockdown mice compared to wild-type counterparts. The latter showed an increase in circulating asprosin levels in response to fasting, with a corresponding significant increase of hepatic cAMP levels and glucose production, whereas these effects were significantly reduced in *Olfr734*-knockout mice [22]. These findings further validate the initial findings of Romere *et al.* (2016) [12], indicating that asprosin is a glucogenic adipose-derived hormone that acts through the OLFR734 receptor. It should be highlighted that the glucose production in asprosin-treated *Olfr734*-knockdown mice was reduced, but was not completely abolished; thus, asprosin may be utilising additional receptors on hepatocytes which are yet to be identified. In addition, the human orthologue for OLFR734, *i.e.* OR4M1, remains to be investigated in relation to asprosin-induced effects.

Furthermore, by creating a mouse model that is representative of NPS at a molecular level (*Fbn1*$^{NPS/+}$) and investigating the effects of asprosin on appetite, Duerrschmid *et al.* (2017) [20] reported asprosin as an orexigenic hormone. Similar to patients with NPS, *Fbn1*$^{NPS/+}$ mice were extremely lean, consumed fewer calories due to low appetite (hypophagia) and had reduced plasma asprosin levels compared to wild-type mice [20]. Notably, asprosin is able to cross the blood brain barrier and activate agouti-related peptide-expressing (AgRP^{+}) neurons (neurons that produce agouti-related protein to promote food intake and reduce energy expenditure) via a G-protein ($G\alpha_s$)-cAMP-PKA pathway [20,23]. As such, asprosin was shown to restore the firing frequency and resting membrane potential of AgRP^{+} neurons in *Fbn1*$^{NPS/+}$ mice. Accordingly, asprosin-treated wild-type mice consumed more calories than non-treated mice, whilst ablation of AgRP^{+} neurons abolished the appetite-stimulating effects of asprosin [20]. Moreover, asprosin reduced the firing frequency and resting membrane potential of neurons that produce pro-opiomelanocortin (POMC) to promote satiety (POMC^{+}

Journal Pre-proof

neurons) [20,23]. In line with these effects, decreased food intake was observed in mice with *Olfr734* knockdown after overnight fasting compared to wild-type mice [24]. Further investigation found that OLFR734 is expressed in $AgRP^+$ neurons, and that the proportion of active $AgRP^+$ neurons is significantly decreased in *Olfr734*$^{-/-}$ mice [24]. Interestingly, in accord with the findings of Duerrschmid *et al.* (2017), asprosin administration in wild-type mice promoted activation of $AgRP^+$ neurons; however, this effect was not observed in *Olfr734*$^{-/-}$ mice [20,24]. These findings suggest that the glucogenic and orexigenic effects of asprosin in mice are elicited through similar pathways via OLFR734 in hepatocytes and $AgRP^+$ neurons, respectively. Of note, Liu *et al.* (2020) [24] also found that asprosin was able to enhance the olfactory performance of mice fed a high-fat diet (HFD) which was otherwise impaired. As OLFR734 is highly expressed in the olfactory bulb, it is important to further explore the role of asprosin in olfaction, particularly since the sense of smell is increasingly linked to the regulation of appetite and palatability [25].

4. The role of asprosin in inflammation and insulin action

Obesity is characterized by the development of a chronic, generalized, low-grade inflammatory state due to increased production of pro-inflammatory mediators from the accumulated adipose tissue which are secreted locally and enter the circulation [4,26,27]. In insulin-sensitive tissues (*e.g.* in skeletal muscle and adipose tissue) obesity-related inflammation can impact on insulin signalling, leading to insulin resistance [28]. Recently, a study by Jung *et al.* (2019) [29] showed that asprosin can bind to myocytes with high affinity and promote insulin resistance. Moreover, asprosin also reduced insulin-stimulated glucose uptake in both a mouse skeletal muscle cell line (C2C12) and human primary skeletal muscle cells [29]. This was achieved by inhibiting the phosphorylation of insulin receptor substrate-1 (IRS-1; a key signalling protein for insulin action) and protein kinase B (Akt; a serine/threonine-specific protein kinase) [29]. In addition, *in vivo* experiments revealed that asprosin treatment led to glucose intolerance and insulin resistance in mice, as well as increased

Journal Pre-proof

endoplasmic reticulum (ER) stress and circulating levels of pro-inflammatory cytokines, such as macrophage chemoattractant protein 1 (MCP-1), tumour necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) [29]. These effects of asprosin were found to be mediated through the protein kinase C delta (PKCδ)-sarco/endoplasmic reticulum Ca2+-ATPase 2 (SERCA2) pathway. PKCδ has been previously found to directly inhibit tyrosine phosphorylation of IRS-1 by phosphorylating IRS-1 at multiple sites in rat hepatocytes [30], whilst another study had found that deletion of PKCδ from muscle improved whole body insulin-sensitivity and insulin signalling in mice [31]. In addition, a PKC-dependent pathway is involved in pro-inflammatory cytokine production [32]. Therefore, PKCδ silencing in the study by Jung *et al.* (2019) [29] reversed the asprosin-induced effects on nuclear translocation of nuclear factor kappa B (NF-κB), ER stress, IRS-1 and Akt phosphorylation [29].

In contrast to the findings by Jung *et al.* (2019) [29], a more recent study found that asprosin treatment significantly upregulated both gene and protein expression of glucose transporter type 4 (GLUT4; a key glucose transporter that is regulated by insulin) and augmented AMPK phosphorylation, resulting in increased glucose uptake by C2C12 muscle cells [14]. This study also reported that asprosin did not affect Akt phosphorylation [14]. As these findings are conflicting, further experimental work is clearly required to elucidate the exact effects of asprosin on skeletal muscle.

Palmitate is a saturated fatty acid that has been found to promote oxidative and ER stress, as well as inflammation and apoptosis in pancreatic β-cells, ultimately impairing insulin secretion [33,34]. Lee *et al*. (2019) [34] showed that palmitate increased asprosin secretion from pancreatic β-cells, and that silencing of asprosin ameliorated the detrimental effects of palmitate, indicating that asprosin mediates these effects of palmitate in an autocrine manner [34]. In this study, asprosin increased intracellular toll-like receptor 4 (TLR4) expression, which consequently increased c-Jun N-terminal kinase (JNK) phosphorylation. Contrary, silencing of TLR4 and JNK suppressed the effects of asprosin on the expression of pro-inflammatory cytokines (TNFα and MCP-1) and apoptosis, whist also improved cell viability and insulin release [34]. These findings indicate that the TLR4-JNK pathway is responsible for asprosin-induced pancreatic β-cell dysfunction. However, the receptor

Journal Pre-proof

responsible for mediating these effects of asprosin on pancreatic β-cells, as well as skeletal muscle cells, remains to be clarified.

5. Asprosin in obesity

A number of studies have reported that circulating asprosin levels are significantly elevated in individuals with increased body weight (overweightness or obesity) [12,35–39]. Similarly, patients with metabolic syndrome have been shown to have significantly higher serum asprosin levels compared to healthy controls, with asprosin concentrations increasing with the number of metabolic syndrome components [39]. In the participants of this study, serum asprosin levels exhibited significant positive correlations with body mass index (BMI), and waist circumference, as well as with glycemic, lipidemic and pro-inflammatory parameters, whilst further sub-categorizing the study participants based on waist circumference revealed that those with abdominal obesity had increased serum asprosin levels compared to those without [39]. In addition, Ugur and Aydin (2019) [36] reported that the concentration of asprosin in both the serum and saliva increased with BMI, with the highest asprosin levels being observed in patients with class III obesity (BMI >45 kg/m^2). In this study, asprosin concentrations were approximately 4-fold and 6-fold higher in the serum and saliva, respectively, of patients with class III obesity compared to the control group, and exhibited significant positive correlations not only with BMI, but also with glucose and low-density lipoprotein (LDL) levels [36]. Asprosin levels in saliva, but not in serum, also correlated positively with circulating triglyceride concentrations [36]. Such correlations between asprosin and glycemic and/or lipidemic parameters were not previously detected in an earlier study by Wang *et al.* (2019) [35], which also reported significantly higher circulating asprosin levels in patients with obesity. The latter study, however, showed that circulating asprosin levels significantly decrease 6 months after bariatric surgery [35]. Notably the existing data on circulating asprosin levels in children with obesity are conflicting. Long *et al.* (2019) [40] have reported significantly lower fasting asprosin serum levels in

Journal Pre-proof

children with obesity compared to a normal-weight control group, with lower asprosin concentrations observed in boys compared to girls in the group with obesity [40]. Similar findings have recently been reported by Corica *et al.* (2021) [41]. However, Silistre and Hatipoğl (2020) found significantly higher concentrations of asprosin in the serum of children with obesity compared to normal-weight counterparts, with no gender-related differences [38].

Interestingly, plasma asprosin levels are significantly elevated in patients with anorexia nervosa compared to healthy controls [42]. When comparing between the restricting type and binge-eating subtype of anorexia nervosa, no significant difference in circulating asprosin levels was observed [42]. Of note, in this study circulating glucose levels were not significantly different between patients with anorexia nervosa and control subjects, and no correlation was observed between plasma asprosin and glucose levels. As asprosin release is induced by fasting [12], this increase in circulating asprosin in patients with anorexia nervosa may be a response to starvation. However, asprosin levels were negatively correlated with the duration of illness in these patients, suggesting that in the long-term circulating asprosin is likely to decline possibly due to reduction in adipose tissue [42].

6. Asprosin in T2DM

A number of studies have investigated the levels of circulating asprosin in patients with T2DM. Indeed, Zhang *et al.* (2019) [43] reported elevated levels of circulating asprosin in patients with T2DM compared to healthy controls, which further independently predicted both fasting blood glucose and triglyceride levels in T2DM [43]. These findings are in accord to those of Li *et al.* (2018) [44] who also found increased plasma asprosin levels in a T2DM cohort, and a significantly positive correlation between plasma asprosin and fasting blood glucose levels. However, no correlation with plasma triglyceride levels was present in this study [44]. Another study with similar findings further reported that 120 minutes after a 75-gram oral glucose tolerance test, circulating asprosin levels decreased in participants with normal glucose tolerance, but not in patients with T2DM [45]. These

Journal Pre-proof

findings suggest an impairment of asprosin response to glucose fluctuations in patients with T2DM [45]. Moreover, higher circulating asprosin levels have also been noted in patients with newly diagnosed T2DM compared to healthy controls, with significant positive correlations to BMI, the homeostatic model assessment of insulin resistance (HOMA-IR) and both fasting blood glucose and triglyceride levels [46]. In addition, plasma asprosin concentrations appear to be even higher in patients with impaired glucose regulation (IGT) compared to patients with newly diagnosed T2DM [47]. This study also revealed significant positive correlations between circulating asprosin levels and HOMA-IR, fasting blood glucose and triglyceride levels, whereas a negative correlation with β-cell function was also noted [47]. Collectively, these findings suggest that asprosin may be an early indicator of glucose and lipid dysregulation and insulin resistance, which could potentially be used as a surrogate biomarker for the risk of developing T2DM. Interestingly, a recent study reported that metformin treatment (2000 mg/day for three months) in patients with T2DM resulted in decreased serum and salivary asprosin levels, which were no longer statistically different from the those of healthy controls [48]. More recently, in a study with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor [49], Jiang *et al.* (2021) [50] found that dapagliflozin treatment (10 mg/day) for 24 weeks significantly reduced serum asprosin levels in patients with newly diagnosed T2DM compared to baseline [50]. Furthermore, at the 24-weeks timepoint of this study serum asprosin levels were also significantly lower in the treatment group compared to the placebo group [50]. These findings suggest that these glucose-lowering drugs prescribed to patients with T2DM act by reducing circulating asprosin levels, but the mechanism mediating this effect remains to be investigated.

As diabetic nephropathy with impaired kidney function is a key long-term complication in patients with diabetes [51,52], a recent study by Deng *et al.* (2020) [53] compared serum asprosin levels in patients with T2DM and normo-albuminuria, micro-albuminuria, or macro-albuminuria, showing that these were significantly elevated in the two latter groups, with even higher levels in the patients with macro-albuminuria [53]. This study further reported a number of correlations between circulating asprosin and markers of kidney function, including a significantly positive correlation with urine

Journal Pre-proof

albumin-to-creatinine ratio and a negative correlation with the estimated glomerular filtration rate [53]. These data suggest that circulating asprosin levels may be related to the progression of kidney disease in patients with T2DM; however, further studies are required to clarify such potential associations.

7. Asprosin in gestational diabetes mellitus

Circulating levels of multiple adipokines are known to exhibit significant changes in women with gestational diabetes mellitus (GDM) [54,55]. Recently a number of studies have reported significantly increased circulating levels of asprosin in GDM [56–58]. Baykus *et al*. (2019) [56] were the first to show increased circulating asprosin levels in women with GDM, as well as in women with pre-eclampsia (especially those with severe pre-eclampsia and macrosomic foetuses) compared to healthy pregnant women [56]. In this study, asprosin levels were also reported to be elevated in neonatal venous and arterial cord blood from women with GDM and pre-eclampsia [56]. These findings were also confirmed by Zhong *et al.* (2020) [57] who further reported significantly higher circulating asprosin levels in women with GDM at both the second trimester (week 18-20) of pregnancy and before delivery compared with healthy pregnant women [57]. Interestingly, in this study circulating asprosin levels between the 24^{th} and 28^{th} gestational week in women with GDM were not statistically different to the control group [57]. This study also reported higher asprosin levels in the umbilical cords of neonates born to mothers with GDM [57]. Furthermore, data from Rezk *et al.* (2020) [58], using a rat model of GDM by injecting rats with 2% streptozotocin at day-3 of pregnancy, showed that plasma asprosin levels were higher in pregnant compared to non-pregnant rats and that rats with GDM exhibited significantly elevated plasma asprosin levels compared to the controls [58]. Notably, plasma asprosin levels were significantly reduced in insulin-treated GDM rats and were higher on day-20 than day-7 in all groups, although changes between groups were seen as early as day-7 [58]. In this animal study, plasma asprosin levels showed positive correlations with BMI, food intake, HOMA-IR, blood glucose and LDL levels, whereas correlated negatively with β-cell function and

Journal Pre-proof

HDL levels [58]. Taken together, the results from these studies suggest that circulating asprosin levels may rise early in the course pregnancy, and could be augmenting glucose production and promoting insulin resistance in GDM.

8. Asprosin and non-alcoholic fatty liver disease (NAFLD)

NAFLD describes the spectrum of metabolic-associated liver diseases that are not related to alcohol consumption and arise due to excess hepatic accumulation of lipids (steatosis) [59]. Excess lipid accumulation in hepatocytes can promote inflammation (NASH; non-alcohol steatohepatitis), which can further progress to liver fibrosis and then liver cirrhosis [59,60]. A recent study by Ke *et al.* (2020) [61] showed that serum asprosin levels were significantly elevated in patients with non-treated NAFLD compared to a healthy control group, whereas the serum levels of the anti-inflammatory adipokine adiponectin were significantly decreased [61]. In the NAFLD group of this study, positive correlations were noted between serum asprosin levels and HOMA-IR, albumin, fasting glucose, and triglyceride levels [61]. Of note, in this study asprosin was independently related to both fasting glucose and triglyceride levels [61]. Given the effects of both asprosin and adiponectin on insulin signalling [29,62], the data by Ke *et al.* (2020) [61] suggest that the change in the levels of these two adipokines may be a contributing factor to the development of insulin resistance in NAFLD. However, recently reported data from a study in 97 patients with NASH showed that serum and salivary levels of asprosin were significantly lower in these patients compared to a control group [63]. It is plausible that circulating asprosin levels may change as NAFLD progresses from simple hepatic steatosis to NASH; however, further investigations are required to explore the role of asprosin in such metabolic-related liver diseases.

9. Asprosin and heart disease

Journal Pre-proof

Dilated cardiomyopathy is a common form of heart disease, which is mainly characterised by impaired left ventricular function due to dilation of the ventricle, resulting in systolic dysfunction [64]. Wen *et al.* (2020) [65] reported that patients with dilated cardiomyopathy had significantly higher circulating asprosin levels compared to a healthy control group [65]. This study also reported that the patients with lower plasma asprosin levels had a greater risk of an adverse cardiovascular event over a 5-year follow-up period compared to those with high plasma asprosin levels [65]. *In vitro* data from this study further showed that asprosin improved cell viability of cardiomyoblasts in a dose-dependent manner under hypoxic conditions [65]. Indeed, a significant reduction in mitochondrial respiration was observed in cardiomyoblasts treated with hydrogen peroxide (H_2O_2); however, the addition of asprosin significantly improved the mitochondrial function in H_2O_2-treated cells. Interestingly, no difference was observed between control cells without H_2O_2 and cells treated with asprosin alone, suggesting that asprosin primarily helps restore mitochondrial function under hypoxic conditions [65]. As one of the underlying mechanisms implicated in dilated cardiomyopathy is mitochondrial dysfunction [64], these findings suggest a potential relevant therapeutic role for asprosin. Moreover, the protective effects of asprosin appear to extend to mesenchymal stromal cells. A study using mesenchymal stromal cells pre-treated with asprosin showed that injecting such cells into infarcted mice hearts improved both the survival of mesenchymal stromal cells and the left ventricular ejection fraction compared to controls, whereas it reduced cardiac fibrosis [66]. This study further reported that asprosin treatment protected mesenchymal stromal cells from H_2O_2-induced reactive oxygen species (ROS) production and apoptosis via upregulation of superoxide dismutase 2 (SOD2) and activation of the ERK1/2 (extracellular signal-regulated kinases) pathway [66]. Although further relevant research is still needed, the emerging evidence for the potentially protective role of asprosin in heart tissue is intriguing.

10. Asprosin and polycystic ovary syndrome (PCOS)

Journal Pre-proof

PCOS is a prevalent endocrine disorder in women of reproductive age, which is characterised by varying combinations of manifestations/symptoms, including anovulation, irregular menstrual cycles, hyperandrogenism and presence of polycystic cysts [67–69]. Notably, PCOS is also closely associated with both obesity (particularly central) and metabolic dysregulation *(e.g.* insulin resistance and dyslipidemia), which increase the risk of developing obesity-related disorders including T2DM and cardiovascular disease [67,69]. Indeed, the majority of women with PCOS have increased body weight, and this increased adiposity (particularly visceral/central) can exacerbate a vicious cycle between insulin resistance and hyperandrogenism [69–71]. Emerging clinical data show that circulating asprosin levels appear to be higher in women with PCOS compared to respective controls [44,72]. Interestingly, in a study by Li *et al.* (2018) [44], which further sub-categorized the studied women with PCOS based on BMI, there was no significant difference in the plasma asprosin levels between those with normal weight and those with overweight/obesity. However, this finding may be attributed to the small sample size of the study groups (12 and 29 women with PCOS, respectively), and thus should be further studied in larger cohorts of women with PCOS [44]. Nevertheless, after adjusting for age in the PCOS group of this study, plasma asprosin levels correlated positively to testosterone levels, as well as to a number of metabolic parameters, including HOMA-IR, fasting glucose and LDL levels [44]. Similar findings have been reported by Alan *et al*. (2018) [72] who showed elevated levels of circulating asprosin in women with PCOS, which also related to insulin resistance [72]. Given that asprosin can promote insulin resistance in skeletal muscle [29], it is plausible that increased circulating asprosin levels can contribute to the development of insulin resistance in PCOS. However, a larger study in Taiwan which included 444 women with PCOS that were recruited over a 7-year period found no difference in circulating asprosin levels compared to a healthy control group [73]. Moreover, a recent study found that circulating asprosin levels were lower in healthy women on oral contraception compared to those not using oral contraceptives, with the highest concentrations noted in the early follicular phase and the mid-luteal phase of the menstrual cycle of women that used or not used oral contraception, respectively [74]. This suggests that oral

Journal Pre-proof

contraception use and the menstrual cycle phase should be controlled for in studies investigating circulating asprosin concentrations in women. This is particularly relevant to studies focusing on PCOS, since women with PCOS frequently exhibit menstrual disorders and/or are on treatment with oral contraceptives. Of note, two of the three studies mentioned above did not recruit women who were on oral contraceptives [72,73]. Overall, the potential role of asprosin in PCOS merits further research, particularly in women with different phenotypes of PCOS and of different ethnic backgrounds.

11. Asprosin and male fertility

Male fertility is dependent on the quality of sperm, including sperm quantity and viability, as well as sperm motility [75]. Interestingly, the mRNA of the known mouse receptor for asprosin, OLFR734, is shown to be highly expressed in mice testes [22,76]. A study by Wei *et al.* (2019) [76] showed no difference in spermiogenesis between 10-week-old male *Olfr734*$^{-/-}$ and wild-type mice, which also had similar testis weight, morphology and histology, as well as body weight and blood glucose levels [76]. However, the ability of the sperm to move in one clear direction was significantly impaired in the *Olfr734*$^{-/-}$ mice of this study [76]. In addition, *Olfr734*$^{-/-}$ mice exhibited a greater proportion of sperm with slow motility and reduced ATP levels, and lacked fertilisation potential compared to wild-type mice [76]. Asprosin treatment had no effect on spermiogenesis; however, it almost restored sperm ATP and cAMP levels, which are essential for the spermatozoon movement in the female reproductive tract, and the fertilisation potential in 40-week-old wild-type mice to that of 10-week-old mice [76]. Notably, these effects were not observed in *Olfr734*$^{-/-}$ mice [76]. Collectively, these findings indicate that asprosin may be implicated in male fertility, although potential associations between asprosin and sperm quality in men are yet to be investigated.

12. Asprosin and exercise

Journal Pre-proof

It is well-documented that significant changes in the levels of circulating adipokines/cytokines can occur as a result of exercise [77,78]. Accordingly, a number of recent studies have reported changes in circulating asprosin levels in response to aerobic and anaerobic exercise. An animal study by Ko *et al.* (2019) [79] investigated the effects of 8 weeks of aerobic exercise (4 days per week) on hepatic asprosin levels in a rat model of streptozotocin-induced type 1 diabetes mellitus (T1DM). In this study, asprosin protein levels in the liver were significantly higher in T1DM rats compared to the control group [79]. However, hepatic asprosin levels significantly decreased in the T1DM rats that underwent aerobic exercise training, which became similar to those in the control group [79]. The levels of hepatic PKA and transforming growth factor beta (TGF-β) also significantly decreased, while AMPK levels increased after this exercise intervention [79]. Studies have shown that hepatic TGFβ1 knockdown and increased hepatic AMPK activity can lower blood glucose levels, by suppressing glucose production, and promote insulin sensitivity [80,81]. As such, the findings from Ko *et al.* (2019) [79] suggest that aerobic exercise lowers asprosin levels, which, in turn, attenuates glucose production via the PKA pathway through TGF-β inhibition and increased AMPK activity [79]. In line with these findings, another study in rats reported that, although there was no difference between the two training modes, continuous and interval swimming training (5 days/week for 8 weeks) significantly reduced serum asprosin levels in rats with metabolic syndrome [82]. In these rats, a significant decrease was also observed in circulating triglyceride, LDL, glucose and total cholesterol levels [82]. Asprosin only positively correlated with glucose levels in the rats with metabolic syndrome, indicating that exercise is effective in lowering circulating asprosin levels and ultimately improving glucose homeostasis [82].

More recently, the acute effects of aerobic exercise (30 minutes of moderately intense aerobic exercise in the morning and the evening) on circulating asprosin levels were examined in adult men with normal weight and overweight/obesity [37]. A significant decrease in serum asprosin levels was reported after exercise in both groups, with a greater decrease being observed in the evening in men with overweight/obesity [37]. Furthermore, these participants also consumed significantly less

Journal Pre-proof

calories compared to those in the normal weight group [37]. Moreover, an acute effort of anaerobic exercise (a single bicycle sprint effort) has been shown to increase circulating levels of asprosin at 15, 30 and 60 min, and 24 hours following the exercise in women, but not in men [83]. In this study, serum leptin levels decreased at 3, 15, and 30 min after the exercise in women, whilst an increase in IL-6 levels was noted at 3, 15, 30, and 60 min after the exercise in men and at 15, 30, 60, and 24 hours following the exercise in women, with a decrease in IL-1β in men at 15, 30, and 60 min after the exercise, and at 15 and 30 min after the exercise in women [83]. Interestingly, the impact of whole-body cryotherapy - which has been reported to improve lipid and adipokine profiles and exert anti-inflammatory and anti-oxidant effects [84,85] - on circulating asprosin levels in menopausal women with metabolic syndrome and hyperglycemia was explored in another study by the same group [86]. In this study, circulating asprosin levels at baseline were significantly higher in women with hyperglycemia compared to those with normoglycemia, without a significant difference between women with metabolic syndrome and healthy menopausal women [86]. Following 20 whole-body cryotherapy sessions (exposure to -130°C for three minutes in a stationary cryogenic chamber), circulating asprosin levels decreased significantly in the healthy menopausal women, menopausal women with metabolic syndrome and menopausal women with hyperglycemia, with no changes in the circulating levels of leptin, adiponectin or irisin in any of the study groups [86]. Accordingly, blood glucose concentrations also decreased significantly after the whole-body cryotherapy sessions, but only in the group of menopausal women with hyperglycemia [86]. In addition, blood glucose concentrations decreased slightly, but not significantly, in the study group of women with metabolic syndrome in response to whole-body cryotherapy and were no longer significantly different from those in the healthy menopausal women. These findings are in accord with those of previous studies which indicate that asprosin plays a role in glucose regulation.

13. Future perspectives and conclusion

Journal Pre-proof

Adipokines play a crucial endocrine role mediating the dynamic communication between adipose tissue and other organs/tissues in order to regulate metabolic homeostasis, as well as multiple other functions of the body. Asprosin is a novel adipokine which appears to play a key role in maintaining normoglycemia during the fasted state by promoting hepatic glucose production and stimulating appetite by acting on $AgRP^{+}$ neurons of the brain [12,20]. Indeed, an increasing body of evidence from both clinical (Table 1) and preclinical (Table 2) studies indicate that this adipokine may play a significant role in metabolism, obesity and related cardio-metabolic diseases. As such, clinical data have revealed elevated circulating levels of asprosin in a number of cardio-metabolic diseases including obesity, T2DM, GDM, NAFLD and PCOS (Table 1). Notably, acute aerobic exercise appears effective in lowering circulating asprosin levels, indicating that relevant lifestyle interventions could impact on asprosin secretion/regulation. Interestingly, animal data also indicate that asprosin may be implicated in male fertility by affecting sperm motility [76], thus suggesting that this recently identified adipokine may exert physiologic effects that extend beyond metabolism. Moreover, *in vitro* studies have found asprosin to elicit pro-inflammatory effects and attenuate insulin secretion and signalling in skeletal muscle and pancreatic β-cells, whereas it has been shown to protect and improve survival of cardiomyoblasts exposed to hypoxic conditions, as well as mesenchymal stromal cells transplanted into infarcted mice hearts (Table 2). To date, asprosin appears to exert its effects by acting on various signalling pathways via a G-protein coupled receptor, namely olfactory receptor OLFR734 in mice (OR4M1 is the human orthologue of OLFR734) and potentially via other receptors, such as TLR4 or other unknown receptors (Figure 2). Overall, the available evidence so far suggests that this novel adipokine may exert pleiotropic physiologic effects (Figure 3). Given this growing body of evidence, further preclinical and clinical research is required in order to fully elucidate the role of asprosin in health and disease, and explore whether it may constitute a potential therapeutic target and/or a biomarker for obesity and related cardio-metabolic diseases.

Journal Pre-proof

Author Contributions

Kiran Shabir: Conceptualization, Writing-Original draft preparation, Literature Search, Visualization; James E. Brown: Writing- Reviewing and Editing, Literature Search, Supervision; Islam Afzal: Writing- Reviewing and Editing, Literature Search, Visualization; Seley Gharanei: Writing- Reviewing and Editing, Literature Search; Martin O. Weickert: Writing- Reviewing and Editing, Literature Search; Thomas M. Barber: Writing- Reviewing and Editing, Literature Search; Ioannis Kyrou: Conceptualization, Writing- Reviewing and Editing, Visualization, Supervision; Harpal S. Randeva: Conceptualization, Writing- Reviewing and Editing, Visualization, Supervision. All authors revised and approved the final manuscript.

Funding

No specific funding was received for doing this work.

Declaration of Competing Interest

The authors declare no conflict of interest.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

KS, JEB, IK and HSR would like to thank the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust and Aston University for their funding support via the Aston University 50th Anniversary Prize PhD studentship scheme.

Journal Pre-proof

Journal Pre-proof

References

[1] M. Blüher, Obesity: global epidemiology and pathogenesis, Nat. Rev. Endocrinol. 15 (2019) 288–298. https://doi.org/10.1038/s41574-019-0176-8.

[2] Y.C. Chooi, C. Ding, F. Magkos, The epidemiology of obesity, Metabolism. 92 (2019) 6–10. https://doi.org/10.1016/j.metabol.2018.09.005.

[3] L.M. Jaacks, S. Vandevijvere, A. Pan, C.J. McGowan, C. Wallace, F. Imamura, D. Mozaffarian, B. Swinburn, M. Ezzati, The obesity transition: stages of the global epidemic, Lancet Diabetes Endocrinol. 7 (2019) 231–240. https://doi.org/10.1016/S2213-8587(19)30026-9.

[4] I. Kyrou, H.S. Randeva, C. Tsigos, G. Kaltsas, M.O. Weickert, Clinical Problems Caused by Obesity, in: K. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D. Trence, A. Vinik, D. Wilson (Eds.), Endotext, MDText.com, Inc., South Dartmouth (MA), 2018. https://www.ncbi.nlm.nih.gov/books/NBK278973/ (accessed April 6, 2021).

[5] I. Kyrou, H.S. Mattu, K. Chatha, H.S. Randeva, Fat Hormones, Adipokines, in: Endocrinol. Hear. Heal. Dis. Integr. Cell. Mol. Endocrinol. Hear., Elsevier Inc., 2016: pp. 167–205. https://doi.org/10.1016/B978-0-12-803111-7.00007-5.

[6] S.S. Choe, J.Y. Huh, I.J. Hwang, J.I. Kim, J.B. Kim, Adipose tissue remodeling: Its role in energy metabolism and metabolic disorders, Front. Endocrinol. (Lausanne). 7 (2016) 30. https://doi.org/10.3389/fendo.2016.00030.

[7] L. Scheja, J. Heeren, The endocrine function of adipose tissues in health and cardiometabolic disease, Nat. Rev. Endocrinol. 15 (2019) 507–524. https://doi.org/10.1038/s41574-019-0230-6.

Journal Pre-proof

[8] X. Su, D. Peng, Adipokines as novel biomarkers of cardio-metabolic disorders, Clin. Chim. Acta. 507 (2020) 31–38. https://doi.org/10.1016/j.cca.2020.04.009.

[9] J.A. Kim, K.M. Choi, Newly Discovered Adipokines: Pathophysiological Link Between Obesity and Cardiometabolic Disorders, Front. Physiol. 11 (2020) 1–8. https://doi.org/10.3389/fphys.2020.568800.

[10] J.E. Brown, Dysregulated adipokines in the pathogenesis of type 2 diabetes and vascular disease, Br. J. Diabetes Vasc. Dis. 12 (2012) 249–254. https://doi.org/10.1177/1474651412464794.

[11] J.I. Mechanick, S. Zhao, W.T. Garvey, The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice, J. Am. Coll. Cardiol. 68 (2016) 1785–1803. https://doi.org/10.1016/j.jacc.2016.06.072.

[12] C. Romere, C. Duerrschmid, J. Bournat, P. Constable, M. Jain, F. Xia, P.K. Saha, M. Del Solar, B. Zhu, B. York, P. Sarkar, D.A. Rendon, M.W. Gaber, S.A. LeMaire, J.S. Coselli, D.M. Milewicz, V.R. Sutton, N.F. Butte, D.D. Moore, A.R. Chopra, Asprosin, a Fasting-Induced Glucogenic Protein Hormone, Cell. 165 (2016) 566–579. https://doi.org/10.1016/j.cell.2016.02.063.

[13] M.R. Davis, E. Arner, C.R.E. Duffy, P.A. De Sousa, I. Dahlman, P. Arner, K.M. Summers, Expression of FBN1 during adipogenesis: Relevance to the lipodystrophy phenotype in Marfan syndrome and related conditions, Mol. Genet. Metab. 119 (2016) 174–185. https://doi.org/10.1016/j.ymgme.2016.06.009.

[14] Y. Zhang, Z. Zhu, W. Zhai, Y. Bi, Y. Yin, W. Zhang, Expression and purification of asprosin in Pichia pastoris and investigation of its increase glucose uptake activity in skeletal muscle through activation of AMPK, Enzyme Microb. Technol. 144 (2021) 109737. https://doi.org/10.1016/j.enzmictec.2020.109737.

Journal Pre-proof

[15] T. Takenouchi, M. Hida, Y. Sakamoto, C. Torii, R. Kosaki, T. Takahashi, K. Kosaki, Severe congenital lipodystrophy and a progeroid appearance: Mutation in the penultimate exon of FBN1 causing a recognizable phenotype, Am. J. Med. Genet. Part A. 161 (2013) 3057–3062. https://doi.org/10.1002/ajmg.a.36157.

[16] L.M. Graul-Neumann, T. Kienitz, P.N. Robinson, S. Baasanjav, B. Karow, G. Gillessen-Kaesbach, R. Fahsold, H. Schmidt, K. Hoffmann, E. Passarge, Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3' terminus of the FBN1-gene, Am. J. Med. Genet. Part A. 152 (2010) 2749–2755. https://doi.org/10.1002/ajmg.a.33690.

[17] A. Jacquinet, A. Verloes, B. Callewaert, C. Coremans, P. Coucke, A. de Paepe, U. Kornak, F. Lebrun, J. Lombet, G.E. Piérard, P.N. Robinson, S. Symoens, L. Van Maldergem, F.G. Debray, Neonatal progeroid variant of Marfan syndrome with congenital lipodystrophy results from mutations at the 3' end of FBN1 gene, Eur. J. Med. Genet. 57 (2014) 230–234. https://doi.org/10.1016/j.ejmg.2014.02.012.

[18] J. Goldblatt, J. Hyatt, C. Edwards, I. Walpole, Further evidence for a marfanoid syndrome with neonatal progeroid features and severe generalized lipodystrophy due to frameshift mutations near the 3' end of the FBN1 gene, Am. J. Med. Genet. Part A. 155 (2011) 717–720. https://doi.org/10.1002/ajmg.a.33906.

[19] L. Krieg, A. Schaffert, M. Kern, K. Landgraf, M. Wabitsch, A.G. Beck-Sickinger, A. Koerner, M. Blüher, M. von Bergen, K. Schubert, An MRM-based multiplexed quantification assay for human adipokines and apolipoproteins, Molecules. 25 (2020) 1–19. https://doi.org/10.3390/molecules25040775.

[20] C. Duerrschmid, Y. He, C. Wang, C. Li, J.C. Bournat, C. Romere, P.K. Saha, M.E. Lee, K.J. Phillips, M. Jain, P. Jia, Z. Zhao, M. Farias, Q. Wu, D.M. Milewicz, V.R. Sutton, D.D. Moore, N.F. Butte, M.J. Krashes, Y. Xu, A.R. Chopra, Asprosin is a centrally acting orexigenic

Journal Pre-proof

hormone, Nat. Med. 23 (2017) 1444–1453. https://doi.org/10.1038/nm.4432.

[21] E. Li, H. Shan, L. Chen, A. Long, Y. Zhang, Y. Liu, L. Jia, F. Wei, J. Han, T. Li, X. Liu, H. Deng, Y. Wang, OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin, Cell Metab. 30 (2019) 319-328.e8. https://doi.org/10.1016/j.cmet.2019.05.022.

[22] E. Li, H. Shan, L. Chen, A. Long, Y. Zhang, Y. Liu, L. Jia, F. Wei, J. Han, T. Li, X. Liu, H. Deng, Y. Wang, OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin, Cell Metab. 30 (2019) 319-328.e8. https://doi.org/10.1016/j.cmet.2019.05.022.

[23] C.G. Bell, A.J. Walley, P. Froguel, The genetics of human obesity, Nat. Rev. Genet. 6 (2005) 221–234. https://doi.org/10.1038/nrg1556.

[24] Y. Liu, A. Long, L. Chen, L. Jia, Y. Wang, The Asprosin–OLFR734 module regulates appetitive behaviors, Cell Discov. 6 (2020) 6–8. https://doi.org/10.1038/s41421-020-0152-4.

[25] L.G. Fine, C.E. Riera, Sense of Smell as the Central Driver of Pavlovian Appetite Behavior in Mammals, Front. Physiol. 10 (2019) 1151. https://doi.org/10.3389/fphys.2019.01151.

[26] R. Cancello, K. Clément, Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue, BJOG An Int. J. Obstet. Gynaecol. 113 (2006) 1141–1147. https://doi.org/10.1111/j.1471-0528.2006.01004.x.

[27] L. Van Beek, M.A. Lips, A. Visser, H. Pijl, A. Ioan-Facsinay, R. Toes, F.J. Berends, K. Willems Van Dijk, F. Koning, V. Van Harmelen, Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance, Metabolism. 63 (2014) 492–501. https://doi.org/10.1016/j.metabol.2013.12.002.

[28] H. Wu, C.M. Ballantyne, Skeletal muscle inflammation and insulin resistance in obesity, J. Clin. Invest. 127 (2017) 43–54. https://doi.org/10.1172/JCI88880.

[29] T.W. Jung, H.C. Kim, H.U. Kim, T. Park, J. Park, U. Kim, M.K. Kim, J.H. Jeong, Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in

Journal Pre-proof

Journal Pre-proof

skeletal muscle, J. Cell. Physiol. 234 (2019) 20888–20899. https://doi.org/10.1002/jcp.28694.

[30] M.W. Greene, N. Morrice, R.S. Garofalo, R.A. Roth, Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cδ, Biochem. J. 378 (2004) 105–116. https://doi.org/10.1042/BJ20031493.

[31] M. Li, S.G. Vienberg, O. Bezy, B.T. O'Neill, C.R. Kahn, Role of PKCδ in insulin sensitivity and skeletal muscle metabolism, Diabetes. 64 (2015) 4023–4032. https://doi.org/10.2337/db14-1891.

[32] E. Kontny, M. Ziólkowska, A. Ryzewska, W.S. Maśliński, Protein kinase C-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), Cytokine. 11 (1999) 839–848. https://doi.org/10.1006/cyto.1998.0496.

[33] M. Nemecz, A. Constantin, M. Dumitrescu, N. Alexandru, A. Filippi, G. Tanko, A. Georgescu, The distinct effects of palmitic and oleic acid on pancreatic beta cell function: The elucidation of associated mechanisms and effector molecules, Front. Pharmacol. 9 (2019) 1554. https://doi.org/10.3389/fphar.2018.01554.

[34] T. Lee, S. Yun, J.H. Jeong, T.W. Jung, Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation, Mol. Cell. Endocrinol. 486 (2019) 96–104. https://doi.org/10.1016/j.mce.2019.03.001.

[35] C.Y. Wang, T.A. Lin, K.H. Liu, C.H. Liao, Y.Y. Liu, V.C.C. Wu, M.S. Wen, T. Sen Yeh, Serum asprosin levels and bariatric surgery outcomes in obese adults, Int. J. Obes. 43 (2019) 1019–1025. https://doi.org/10.1038/s41366-018-0248-1.

[36] K. Ugur, S. Aydin, Saliva and blood asprosin hormone concentration associated with obesity, Int. J. Endocrinol. 2019 (2019) 1–8. https://doi.org/10.1155/2019/2521096.

[37] H.İ. Ceylan, Ö. Saygın, Ü. Özel Türkcü, Assessment of acute aerobic exercise in the morning versus evening on asprosin, spexin, lipocalin-2, and insulin level in overweight/obese versus

Journal Pre-proof

normal weight adult men, Chronobiol. Int. 37 (2020) 1252–1268. https://doi.org/10.1080/07420528.2020.1792482.

[38] E.S. Silistre, H.U. Hatipoğl, Increased serum circulating asprosin levels in children with obesity, Pediatr. Int. 62 (2020) 467–476. https://doi.org/10.1111/ped.14176.

[39] T. Hong, J.-Y. Li, Y. Wang, X.-Y. Qi, Z.-Z. Liao, P. Bhadel, L. Ran, J. Yang, B. Yan, J.-H. Liu, X.-H. Xiao, High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome, Int. J. Endocrinol. 2021 (2021) 1–7. https://doi.org/https://doi.org/10.1155/2021/6622129.

[40] W. Long, X. Xie, C. Du, Y. Zhao, C. Zhang, D. Zhan, Z. Li, Q. Ning, X. Luo, Decreased Circulating Levels of Asprosin in Obese Children, Horm. Res. Paediatr. 91 (2019) 271–277. https://doi.org/10.1159/000500523.

[41] D. Corica, T. Aversa, M. Currò, A. Tropeano, G. Pepe, A. Alibrandi, R. Ientile, M. Wasniewska, Asprosin serum levels and glucose homeostasis in children with obesity, Cytokine. 142 (2021) 155477. https://doi.org/10.1016/j.cyto.2021.155477.

[42] Y. Hu, Y. Xu, Y. Zheng, Q. Kang, Z. Lou, Q. Liu, H. Chen, Y. Ji, L. Guo, C. Chen, L. Ruan, J. Chen, Increased plasma asprosin levels in patients with drug-naive anorexia nervosa, Eat. Weight Disord. 1 (2020) 3. https://doi.org/10.1007/s40519-020-00845-3.

[43] L. Zhang, C. Chen, N. Zhou, Y. Fu, X. Cheng, Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride, Clin. Chim. Acta. 489 (2019) 183–188. https://doi.org/10.1016/j.cca.2017.10.034.

[44] X. Li, M. Liao, R. Shen, L. Zhang, H. Hu, J. Wu, X. Wang, H. Qu, S. Guo, M. Long, H. Zheng, Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases, Mediators Inflamm. 2018 (2018). https://doi.org/10.1155/2018/7375294.

Journal Pre-proof

[45] X. Zhang, H. Jiang, X. Ma, H. Wu, Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus, J. Diabetes Investig. 11 (2020) 349–355. https://doi.org/10.1111/jdi.13148.

[46] S. Naiemian, M. naeemipour, M. Zarei, M.L. Najafi, A. Gohari, M.R. Behroozikhah, H. Heydari, M. Miri, Serum concentration of asprosin in new-onset type 2 diabetes, Diabetol. Metab. Syndr. 12 (2020). https://doi.org/10.21203/rs.3.rs-15208/v1.

[47] Y. Wang, H. Qu, X. Xiong, Y. Qiu, Y. Liao, Y. Chen, Y. Zheng, H. Zheng, Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion, Mediators Inflamm. 2018 (2018). https://doi.org/10.1155/2018/9471583.

[48] N. Gozel, F. Kilinc, Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin, Endokrynol. Pol. (2020). https://doi.org/10.5603/ep.a2020.0059.

[49] A. Avogaro, A. Giaccari, P. Fioretto, S. Genovese, F. Purrello, F. Giorgino, S. Del Prato, A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus, Expert Rev. Clin. Pharmacol. 10 (2017) 763–772. https://doi.org/10.1080/17512433.2017.1322507.

[50] A. Jiang, Z. Feng, L. Yuan, Q. Li, Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus, Diabetol. Metab. Syndr. 13 (2021) 1–6. https://doi.org/10.21203/rs.3.rs-128673/v1.

[51] J.L. Gross, M.J. De Azevedo, S.P. Silveiro, L.H. Canani, M.L. Caramori, T. Zelmanovitz, Diabetic nephropathy: Diagnosis, prevention, and treatment, Diabetes Care. 28 (2005) 164–176. https://doi.org/10.2337/diacare.28.1.164.

[52] S. Dronavalli, I. Duka, G.L. Bakris, The pathogenesis of diabetic nephropathy, Nat. Clin. Pract.

Journal Pre-proof

Endocrinol. Metab. 4 (2008) 444–452. https://doi.org/10.1038/ncpendmet0894.

[53] X. Deng, L. Zhao, C. Guo, L. Yang, D. Wang, Y. Li, H. Xia, C. Wang, Z. Cai, L. Li, Z. Zhao, G. Yuan, Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes, Diabetes, Metab. Syndr. Obes. Targets Ther. 13 (2020) 4341–4351. https://doi.org/10.2147/DMSO.S283413.

[54] J.M. Atègbo, O. Grissa, A. Yessoufou, A. Hichami, K.L. Dramane, K. Moutairou, A. Miled, A. Grissa, M. Jerbi, Z. Tabka, N.A. Khan, Modulation of Adipokines and Cytokines in Gestational Diabetes and Macrosomia, J. Clin. Endocrinol. Metab. 91 (2006) 4137–4143. https://doi.org/10.1210/jc.2006-0980.

[55] M. Fasshauer, M. Blüher, M. Stumvoll, Adipokines in gestational diabetes, Lancet Diabetes Endocrinol. 2 (2014) 488–499. https://doi.org/10.1016/S2213-8587(13)70176-1.

[56] Y. Baykus, S. Yavuzkir, S. Ustebay, K. Ugur, R. Deniz, S. Aydin, Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus, Peptides. 120 (2019) 170132. https://doi.org/10.1016/j.peptides.2019.170132.

[57] L. Zhong, Y. Long, S. Wang, R. Lian, L. Deng, Z. Ye, Z. Wang, B. Liu, Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study, Placenta. 93 (2020) 17–22. https://doi.org/10.1016/j.placenta.2020.02.004.

[58] M.Y. Rezk, A. Elkattawy, R.A. Fouad, Plasma Asprosin Levels Changes in Pregnant and Non-Pregnant Rats with and without Gestational Diabetes, Int. J. Med. Res. Heal. Sci. (2020) 54–63.

[59] S.L. Friedman, B.A. Neuschwander-Tetri, M. Rinella, A.J. Sanyal, Mechanisms of NAFLD development and therapeutic strategies, Nat. Med. 24 (2018) 908–922.

Journal Pre-proof

https://doi.org/10.1038/s41591-018-0104-9.

[60] M. Trauner, M. Arrese, M. Wagner, Fatty liver and lipotoxicity, Biochim. Biophys. Acta - Mol. Cell Biol. Lipids. 1801 (2010) 299–310. https://doi.org/10.1016/j.bbalip.2009.10.007.

[61] F. Ke, G. Xue, X. Jiang, F. Li, X. Lai, M. Zhang, Y. Shen, L. Gao, Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease, Cytokine. 134 (2020) 155184. https://doi.org/10.1016/j.cyto.2020.155184.

[62] P. Ahlstrom, E. Rai, S. Chakma, H.H. Cho, P. Rengasamy, G. Sweeney, Adiponectin improves insulin sensitivity via activation of autophagic flux, J. Mol. Endocrinol. 59 (2017) 339–350. https://doi.org/10.1530/JME-17-0096.

[63] U. Cosar, K. Ugur, A.R. Fazıl, M. Yardım, S. Aydın, Evaluation of serum and salivary subfatin and asprosin hormone levels in patients with nonalcoholic steatohepatisis, Endocr. Abstr. 70 (2020). https://doi.org/10.1530/endoabs.70.aep262.

[64] J.L. Jefferies, J.A. Towbin, Dilated cardiomyopathy, Lancet. 375 (2010) 752–762. https://doi.org/10.1016/S0140-6736(09)62023-7.

[65] M.S. Wen, C.Y. Wang, J.K. Yeh, C.C. Chen, M.L. Tsai, M.Y. Ho, K.C. Hung, I.C. Hsieh, The role of Asprosin in patients with dilated cardiomyopathy, BMC Cardiovasc. Disord. 20 (2020) 1–8. https://doi.org/10.1186/s12872-020-01680-1.

[66] Z. Zhang, Y. Tan, L. Zhu, B. Zhang, P. Feng, E. Gao, C. Xu, X. Wang, W. Yi, Y. Sun, Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway, Life Sci. 231 (2019) 116554. https://doi.org/10.1016/j.lfs.2019.116554.

[67] O. Gluszak, U. Stopinska-Gluszak, P. Glinicki, R. Kapuscinska, H. Snochowska, W. Zgliczynski, R. Debski, Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome, ISRN Endocrinol. 2012 (2012) 1–7. https://doi.org/10.5402/2012/569862.

Journal Pre-proof

[68] R.L. Rosenfield, D.A. Ehrmann, The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited, Endocr. Rev. 37 (2016) 467–520. https://doi.org/10.1210/er.2015-1104.

[69] I. Kyrou, M.O. Weickert, H.S. Randeva, Diagnosis and management of polycystic ovary syndrome (PCOS), in: Endocrinol. Diabetes Case Stud. Quest. Comment., Springer-Verlag London Ltd, 2015: pp. 99–113. https://doi.org/10.1007/978-1-4471-2789-5_13.

[70] T.M. Barber, M.I. McCarthy, J.A.H. Wass, S. Franks, Obesity and Polycystic Ovary Syndrome, Clin. Endocrinol. (Oxf). 65 (2006) 137–145. https://doi.org/10.1111/j.1365-2265.2006.02587.x.

[71] S. Sam, Obesity and polycystic ovary syndrome, Obes. Manag. 3 (2007) 69–73. https://doi.org/10.1089/obe.2007.0019.

[72] M. Alan, B. Gurlek, A. Yilmaz, M. Aksit, B. Aslanipour, İ. Gulhan, C. Mehmet, C.E. Taner, Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome, Gynecol. Endocrinol. (2018) 1–4. https://doi.org/10.1080/09513590.2018.1512967.

[73] C.L. Chang, S.Y. Huang, Y.C. Hsu, T.H. Chin, Y.K. Soong, The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients, Sci. Rep. 9 (2019) 6447. https://doi.org/10.1038/s41598-019-42061-9.

[74] A.N. Leonard, A.L. Shill, A.E. Thackray, D.J. Stensel, N.C. Bishop, Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women, Eur. J. Appl. Physiol. (2020). https://doi.org/10.1007/s00421-020-04570-8.

[75] N.O. Palmer, H.W. Bakos, T. Fullston, M. Lane, Impact of obesity on male fertility, sperm function and molecular composition, Spermatogenesis. 2 (2012) 253–263.

Journal Pre-proof

https://doi.org/10.4161/spmg.21362.

[76] F. Wei, A. Long, Y. Wang, The Asprosin-OLFR734 hormonal signaling axis modulates male fertility, Cell Discov. 5 (2019) 55. https://doi.org/10.1038/s41421-019-0122-x.

[77] S. Golbidi, I. Laher, Exercise Induced Adipokine Changes and the Metabolic Syndrome, J. Diabetes Res. 2014 (2014) 1–16. https://doi.org/10.1155/2014/726861.

[78] A.M. Gonzalez-Gil, L. Elizondo-Montemayor, The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: A review, Nutrients. 12 (2020) 1. https://doi.org/10.3390/nu12061899.

[79] J.R. Ko, D.Y. Seo, T.N. Kim, S.H. Park, H. Kwak, Aerobic Exercise Training Decreases Hepatic Asprosin in Diabetic Rats, J. Clin. Med. (2019) 666.

[80] Q. Pan, Y. Chen, H. Yan, W. Yang, Z. Shen, S.A. Dahanayaka, S. Guo, Regulation of Hepatic Glucose Production by Transforming Growth Factor Beta 1 via Protein Kinase A, Diabetes. 67 (2018) 2441-PUB. https://doi.org/10.2337/db18-2441-pub.

[81] J. Cao, S. Meng, E. Chang, K. Beckwith-Fickas, L. Xiong, R.N. Cole, S. Radovick, F.E. Wondisford, L. He, Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK), J. Biol. Chem. 289 (2014) 20435–20446. https://doi.org/10.1074/jbc.M114.567271.

[82] H. Nakhaei, M. Mogharnasi, H. Fanaei, Effect of swimming training on levels of asprosin, lipid profile, glucose and insulin resistance in rats with metabolic syndrome, Obes. Med. 15 (2019) 100111. https://doi.org/10.1016/j.obmed.2019.100111.

[83] M. Wiecek, J. Szymura, M. Maciejczyk, M. Kantorowicz, Z. Szygula, Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines - A comparison between sexes, Front. Physiol. 9 (2018) 1–12. https://doi.org/10.3389/fphys.2018.01782.

Journal Pre-proof

[84] E. Ziemann, R.A. Olek, T. Grzywacz, J. Antosiewicz, S. Kujach, M. Łuszczyk, M. Smaruj, E. Śledziewska, R. Laskowski, Whole-body cryostimulation as an effective method of reducing low-grade inflammation in obese men, J. Physiol. Sci. 63 (2013) 333–343. https://doi.org/10.1007/s12576-013-0269-4.

[85] A. Lubkowska, W. Dudzińska, I. Bryczkowska, B. Dołęgowska, Body Composition, Lipid Profile, Adipokine Concentration, and Antioxidant Capacity Changes during Interventions to Treat Overweight with Exercise Programme and Whole-Body Cryostimulation, Oxid. Med. Cell. Longev. 2015 (2015). https://doi.org/10.1155/2015/803197.

[86] M. Wiecek, J. Szymura, J. Sproull, Z. Szygula, Decreased Blood Asprosin in Hyperglycemic Menopausal Women as a Result of Whole-Body Cryotherapy Regardless of Metabolic Syndrome, J. Clin. Med. 8 (2019) 1428. https://doi.org/10.3390/jcm8091428.

Biographical Information and Photographs of Authors:

Mrs. Kiran Shabir:

Mrs. Kiran Shabir has a First Class Honours degree in Biomedical Science from Aston University, and is completing her PhD at Aston Medical School. Mrs. Kiran Shabir is also a research assistant at the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. Her research focuses on the function of different adipose tissue depots and the links between adipose tissue and inflammation, as well as on type 2 diabetes, and cardiovascular disease.

Journal Pre-proof

Dr. James E. Brown:

Dr. James Brown is an Associate professor of Biomedical Science. He graduated with a PhD from Wolverhampton University and worked as a post-doctoral scientist at Wolverhampton University, Warwick University and Aston University before becoming a Lecturer in Biomedical Science at Aston University in 2013. His research interests are obesity and adipocyte-secreted factors, type 2 diabetes in extremes of age, and ageing.

Mr Islam Afzal:

Mr. Islam Afzal has obtained his Bachelors in Medical Sciences from the University of Birmingham, and subsequently obtained multiple post-graduate qualifications in the fields of vascular biology and cardiovascular science, as well as a MBA from Aston University. Currently, Mr. Afzal is employed by KPMG and holds an honorary research fellow appointment at Aston University, whilst he has previously received a Marie Curie Fellowship (collaboration with Hospital Clinic Barcelona). Mr. Afzal is an experienced biomedical researcher with over 15 years of experience in the fields of cellular

Journal Pre-proof

and molecular biology, and his research interests are presently focused on diabetes, metabolism and the role of adipose tissue and skeletal muscle in glucose homeostasis.

Dr. Seley Gharanei:

Dr. Seley Gharanei is a research scientist at the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, and holds an honorary postdoctoral fellowship at the University of Warwick. Dr. Gharanei completed her PhD in diabetes and neurodegeneration at the University of Birmingham, where she also worked in cancer epigenetics as a research associate. Her current research is focused on metabolic dysfunction, diabetes, obesity, adipose tissue biology and inflammation, as well as on pregnancy complications. Dr. Gharanei has previously worked at the University of Warwick as a postdoctoral researcher in the reproductive health and endocrinology departments.

Professor Martin O. Weickert:

Professor Martin O. Weickert has been working in leading University Teaching Hospitals (Augsburg University Teaching Hospital, Ludwig Maximilian University (LMU) Munich, 1997- 2003; Charité University Medicine Berlin, Germany, 2003-2009; and German Institute of Human Nutrition, Potsdam-Rehbruecke 2003-2009). He received his MD for his thesis “Development of an automatic

Journal Pre-proof

immuno-assay for the direct measurement of DHEA-S in serum" in 1997 from the University of Ulm. In June 2009, Prof. Weickert was appointed to the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust as a Consultant Physician for Endocrinology and Diabetes, to develop and lead the Neuroendocrine Tumour (NET) Services in the Trust. Prof. Weickert has transformed the NET Services in the Trust and had successfully applied for ENETS Centre of Excellence status in 2014. Prof. Weickert's research focuses on Neuroendocrine Tumours, as well as Metabolic research. He is experienced in challenge tests in a nutritional context, using state of the art methodologies, such as clamps, tracer studies, molecular methods and advanced imaging techniques. Between 2005 and 2021, Prof. Weickert published more than 135 research papers in high impact, peer reviewed, international, scientific journals; h-index 37.

Dr. Thomas M. Barber:

Dr. Barber is an Associate Professor and Honorary Consultant Endocrinologist at the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW). His research background includes the genetic and metabolic features of Polycystic Ovary Syndrome with award of DPhil from the University of Oxford, and the prestigious 'Society for Endocrinology Clinical Prize Lecture' and 'University of Oxford Medical Sciences Divisional Research Prize' in 2009. Dr. Barber has published >100 papers in leading peer-reviewed journals (H-index 29; i10-index 49), including a recent paper in Lancet Diabetes and Endocrinology on ethnic-specific cut-points for obesity. Dr. Barber presents regularly as an invited speaker at scientific meetings both nationally and internationally. He engages regularly with national media on topics relating to human metabolism and Obesity. As scientific lead for the UHCW Human Metabolism Research Unit, his current research interests include the impact

Journal Pre-proof

of human metabolism on the development of Obesity, and novel strategies to prevent and manage Obesity and Diabetes Mellitus within the populace. As Clinical Lead for the Obesity service at UHCW, Dr. Barber combines clinical duties with clinical and translational research.

Dr. Ioannis Kyrou:

Dr. Ioannis Kyrou has a Medical Diploma (Athens Medical School, Greece), a PhD in Medicine (Warwick Medical School, UK), and a Master in Education (Aston University, UK). Dr. Kyrou is an Associate Professor of Metabolic Medicine, Nutrition and Endocrinology at Coventry University and a GMC registered Endocrinologist at the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, as well as an Honorary Associate Professor at both Warwick and Aston Medical Schools. Dr. Kyrou has over 15 years of clinical and translational research experience in the field of cardio-metabolic diseases, endocrinology, nutrition, aging and public health, having led multiple research studies in these subjects. His current research focuses on obesity/diabetes, metabolism, nutrition, physical activity/exercise, NAFLD, PCOS, cardiovascular and mental health, with a particular interest in biomarkers and elderly populations. To date, his overall research output has resulted in important publications in high-impact, peer-reviewed, biomedical journals (>80 papers in PubMed; >4100 citations; h-index: 28), as well as in numerous announcements in national and international biomedical congresses. In addition, Dr. Kyrou has also authored more than 22 chapters in biomedical textbooks. Finally, Dr. Kyrou is also a Fellow of the UK Higher Education Academy and a member of multiple scientific/medical societies.

Journal Pre-proof

Prof. Harpal S. Randeva:

Prof. Harpal S. Randeva graduated in Medicine in 1989 from the University of Dundee, and is a clinical academic at Warwick Medical School, University of Warwick, as well as a Consultant in Endocrinology, Diabetes & Metabolism at University Hospital Coventry & Warwickshire (UHCW), NHS Trust. Prof. Randeva is the Head of Endocrinology, Diabetes & Metabolism at the Warwickshire Institute for the Study of Diabetes, Endocrinology & Metabolism (WISDEM) and the Director of R&D at UHCW, having just stepped down as Clinical Director for Medicine. Prof. Randeva is a Fellow of the Academy of Translational Medicine, Fellow of the Royal College of Physicians; Royal Society of Medicine and Association of Physicians of England & Ireland. He has been involved in biomedical research since his medical training years in Oxford and London, with a primary interest in metabolism, diabetes, obesity, PCOS, NAFLD and other dysmetabolic states. He is leading a multidisciplinary research team at UHCW & University of Warwick with significant experience in clinical trials and translational research. Prof. Randeva has published >200 papers in leading peer-reviewed journals (H-index: 63; >13000 citations), and presents regularly as an invited speaker at both national and international scientific meetings.

Journal Pre-proof

Journal Pre-proof

Table 1. Summary of key findings from clinical studies investigating circulating asprosin levels.

Study/Reference	Cohort details	Main findings
Neonatal progeroid syndrome (NPS)		
Romere *et al.* (2016) [12]	Healthy control group (*n*=2) Patients with heterozygous *FBN1* frameshift mutation with proximal truncation (*n*=2) Patients with NPS with distal truncation (*n*=2)	Patients with NPS showed the greatest reduction in plasma asprosin compared to healthy controls.
Obesity		
Romere *et al.* (2016) [12]	Healthy control group (*n*=7) Patients with obesity & insulin resistance (*n*=8)	Plasma asprosin levels were significantly increased in patients with obesity and insulin resistance.
Ugur and Aydin (2019) [36]	Participants with; Low weight (*n*=8) Normal weight (*n*=44) Overweight (*n=19*) Obesity: Class I (*n*=10); Class II (*n*=13); Class III (*n*=22)	Serum and salivary asprosin levels increased with body mass index (BMI), with the lowest levels found in the low weight group and the highest in patients with class III obesity.
Wang *et al.,* (2019) [35]	Healthy control group (*n*=57) Patients with obesity (*n*=117)	Significantly higher plasma asprosin levels in patients with obesity. Significantly lower plasma asprosin levels 6-months post-bariatric surgery.
Hong *et al* (2021) [39]	Healthy control group (*n*=162) Patients with metabolic syndrome (*n*=131)	Serum asprosin levels were significantly elevated in patients with metabolic syndrome and increased with the number of metabolic syndrome components. Serum asprosin levels were also significantly higher in participants with abdominal obesity compared to those without abdominal obesity.

Journal Pre-proof

Long *et al.* (2019) [40]	Normal-weight children (*n*=40) Children with obesity (*n*=47)	Circulating asprosin levels were lower in children with obesity compared to healthy controls. Boys with obesity had lower circulating asprosin levels than girls, but this difference was not observed in the control group.
Corica *et al.* (2021) [41]	Normal-weight children (n=24) Children with obesity (*n*=43)	Fasting asprosin was significantly lower in children with obesity. When comparing the entire study cohort, boys had lower fasting asprosin levels than girls.
Silistre and Hatipoğl (2020) [38]	Normal-weight children (*n*=60) Overweight children (*n*=54) Children with obesity (*n*=44)	Serum asprosin was significantly higher in overweight children and more so in children with obesity, compared to normal-weight controls.
Anorexia nervosa		
Hu *et al.* (2020) [42]	Healthy control group (*n*=47) Patients with anorexia nervosa (*n*=46)	Plasma asprosin levels increased in patients with anorexia nervosa compared to the healthy control group.
Type 2 diabetes mellitus (T2DM)		
Wang *et al.* (2018) [47]	Participants with; Normal glucose regulation (*n*=52) Impaired glucose regulation (*n*=40) T2DM (*n*=51)	Patients with impaired glucose regulation and patients with T2DM had significantly elevated levels of plasma asprosin compared to those with normal glucose regulation. The highest plasma asprosin levels were observed in the group of patients with impaired glucose regulation.
Li *et al.* (2018) [44]	Healthy control group (*n*=66) Patients with PCOS (*n*=41) Patients with T2DM (*n*=53)	Plasma asprosin levels were higher in patients with T2DM compared to the healthy control group. Asprosin levels were also higher in women with PCOS than in healthy controls, but lower than in patients with T2DM.
Zhang *et al.* (2019) [43]	Healthy control group (*n*=86) Patients with T2DM (*n*=84)	Patients with T2DM had significantly higher serum asprosin levels than the healthy control group.
Zhang *et al.* (2019) [45]	Normal glucose tolerance (NGT) (*n*=60) Patients with T2DM (*n*=60)	Fasting and postprandial asprosin levels were significantly elevated in patients with T2DM compared to participants with NGT. Circulating asprosin levels decreased in response to a 75-gram oral glucose tolerance test only in participants with NGT.

Journal Pre-proof

Naiemian *et al.* (2020) [46]	Healthy control group (*n*=97) Patients with new-onset T2DM (*n*=97)	Patients with new-onset T2DM had significantly higher serum asprosin levels than the healthy control group.
Gozel and Kilinc (2020) [48]	Healthy control group (*n*=30) Patients with newly diagnosed T2DM (*n*=30)	Salivary and plasma asprosin levels were significantly higher in patients with newly diagnosed T2DM compared to the healthy control group. After 3 months of metformin treatment, salivary and plasma asprosin levels decreased, and were no longer significantly different compared to those in the healthy control group.
Deng *et al.* (2020) [53]	T2DM patients with; Normo-albuminuria (*n*=107) Micro-albuminuria (*n*=80) Macro-albuminuria (*n*=20)	Compared to patients with T2DM and normo-albuminuria, serum asprosin levels were significantly increased in patients with T2DM and micro-albuminuria, and more so in those with macro-albuminuria.
Jiang *et al.* (2021) [50]	Patients with newly diagnosed T2DM; Placebo group (*n*=10) Dapagliflozin group (*n*=19)	Serum asprosin levels significantly decreased after 24 weeks in patients receiving dapagliflozin (10 mg/day) compared to baseline. Serum asprosin levels were significantly lower in the dapagliflozin group compared to the placebo group at 24 weeks.
Gestational diabetes mellitus (GDM)		
Baykus *et al.* (2019) [56]	Healthy pregnant women (*n*=30) Pregnant women with; GDM (*n*=30) pre-eclampsia (*n*=30) severe pre-eclampsia (*n*=30) intrauterine growth retardation (*n*=30) macrosomic foetuses (*n*=29)	Maternal blood asprosin levels were significantly elevated in pregnant women with GDM, pre-eclampsia, severe pre-eclampsia and macrosomic foetuses compared to healthy pregnant women. However, blood asprosin was significantly lower in women with intrauterine growth retardation compared to healthy pregnant women. A similar trend was also observed in arterial and venous cord blood of the studied newborns.
Zhong *et al.* (2020) [57]	Pregnant women with; Normal glucose tolerance (*n*=40) GDM (*n*=40)	Compared to pregnant women with normal glucose tolerance, women with GDM had significantly higher blood asprosin levels at 18-20 gestational week and before delivery. No difference was observed in the blood asprosin levels at 24-28 weeks of gestation. Asprosin levels in the umbilical plasma of women with GDM was also higher compared to the control group.

Journal Pre-proof

Polycystic ovary syndrome (PCOS)		
Alan *et al*. (2018) [72]	Healthy women (*n*=78) Women with PCOS (*n*=78)	Circulating asprosin levels were significantly elevated in women with PCOS compared to the healthy control group.
Li *et al.* (2018) [44]	Healthy women (*n*=66) Women with PCOS (*n*=41) Women with T2DM (*n*=53)	Plasma asprosin levels in women with PCOS were significantly higher compared to healthy controls. No difference was observed between normal-weight women with PCOS and women with PCOS and overweight/obesity.
Chang *et al.* (2019) [73]	Healthy women (*n*=156) Women with PCOS (*n*=444)	No difference in circulating asprosin levels were observed in women with PCOS compared to healthy controls.
Oral contraceptive (OC) use		
Leonard *et al*. (2020) [74]	Trained OC users (*n*=8) Trained non-OC users (*n*=6) Untrained OC users (*n*=10) Untrained non-OC users (*n*=8)	Plasma asprosin levels were lower in OC users compared to non-OC users. The highest asprosin concentrations were noted in the early follicular phase and the mid-luteal phase of the menstrual cycle of OC users and non-OC users, respectively. Significant changes in plasma asprosin were observed during the menstrual cycle of untrained, but not trained, women.
Non-alcoholic fatty liver disease (NAFLD)		
Ke *et al*. (2020) [61]	Healthy control group (*n*=50) Patients with NAFLD (*n*=43)	Serum asprosin levels were significantly elevated in patients with NAFLD compared to healthy controls.
Cosar *et al.* (2020) [63]	Healthy control group (*n*=30) Patients with non-alcoholic steatohepatitis (NASH); stage 1 (*n*=30); stage 2 (*n*=30); stage 3 (*n*=30); stage 4 (*n*=22)	Serum and salivary asprosin levels of patients with NASH were significantly lower than those of the healthy control group.
Dilated cardiomyopathy		
Wen *et al.* (2020)[65]	Healthy control subjects (*n*=50) Patients with dilated cardiomyopathy (*n*=50)	Serum asprosin levels of patients with dilated cardiomyopathy were higher compared to healthy control subjects.

Journal Pre-proof

Effects of exercise & whole-body cryotherapy sessions		
Wiecek *et al.* (2018) [83]	Adults undergoing a single acute anaerobic exercise: Men (*n*=10); Women (*n*=10)	Circulating asprosin levels were only increased in women 15, 30, 60 minutes and 24 hours after an acute anaerobic workout.
Ceylan *et al.* (2020) [37]	Adults undergoing a single acute aerobic exercise session in the morning and evening: Normal-weight group (*n*=10) Patients with overweight/obesity (*n*=10)	Significant decreases serum asprosin levels after exercise in both groups, with a greater decrease in the evening in men with overweight/obesity.
Wiecek *et al.* (2019) [86]	Healthy menopausal women (*n*=18) Menopausal women with: metabolic syndrome (*n*=19) hyperglycemia (*n*=15) normoglycemia (*n*=22)	At baseline, significantly higher circulating asprosin levels in women with hyperglycemia compared to those with normoglycemia, but no difference between women with metabolic syndrome and healthy menopausal women. After 20 whole-body cryotherapy sessions, circulating asprosin levels decreased significantly in healthy menopausal women, menopausal women with metabolic syndrome and menopausal women with hyperglycemia.

Journal Pre-proof

Journal Pre-proof

Table 2. Summary of key findings from preclinical studies investigating asprosin.

Study/Reference	Experimental model(s)	Main findings
Romere *et al.* (2016) [12]	Mouse; *in vitro*	Asprosin is secreted by white adipose tissue and targets the liver by binding to a G-protein coupled receptor on the surface of hepatocytes. Asprosin activates a G protein-cAMP-PKA pathway resulting in increased secretion of glucose by hepatocytes.
Duerrschmid *et al.* (2017) [20]	Mouse	Asprosin can cross the blood-brain barrier and activate $AgRP^{+}$ neurons in the brain by binding to a G-protein coupled receptor and activating a G-protein-cAMP-PKA pathway. Asprosin can also inhibit the activation of $POMC^{+}$ neurons via a GABA-dependent pathway. Thus, asprosin can increase appetite.
Jung *et al*. (2019) [29]	Mouse; *in vitro*	Asprosin expression is increased in the visceral adipose tissue of mice fed a high fat diet. Treatment of skeletal muscle cells with asprosin increased expression of endoplasmic reticulum stress and pro-inflammatory markers. Asprosin treatment decreased insulin receptor substrate-1 and protein kinase B phosphorylation, resulting in attenuated insulin signalling. These effects of asprosin were mediated through the PKCδ pathway.
Li *et al.* (2019) [21]	Mouse; *in vitro*	Asprosin promotes hepatic glucose production through the OLFR734 receptor in mice. The effects of asprosin on cAMP levels and hepatic glucose production are significantly reduced in mice with liver-specific *Olfr734* knockdown.
Lee *et al*. (2019) [34]	*In vitro*	Increased expression and secretion of asprosin in palmitate-treated pancreatic β-cells. The effects of palmitate on inflammation, cell viability and insulin secretion are mediated by asprosin via the TLR4/JNK pathway.
Wei *et al.* (2019) [76]	Mouse	Sperm from *Olfr734*$^{-/-}$ mice have slow motility and significantly reduced fertilisation potential. Asprosin treatment can enhance sperm motility and fertilisation potential of 40-week old mice to that of 10-week old mice, but these effects are diminished in *Olfr734*$^{-/-}$ mice.
Ko *et al.* (2019) [79]	Rat	Hepatic asprosin levels were higher in rats with streptozotocin-induced T1DM, but significantly decreased in response to aerobic exercise. Hepatic PKA and TGFβ levels decreased, but AMPK increased after aerobic exercise. These findings suggest that

Journal Pre-proof

		aerobic exercise lowers hepatic asprosin, which in turn attenuates hepatic glucose production via a PKA pathway and TGFβ inhibition.
Nakhaei *et al.* (2019) [82]	Rat	Continuous and interval swimming training for 8 weeks significantly reduced serum asprosin levels in rats with metabolic syndrome. No difference was noted between these two training modes.
Zhang *et al.* (2019) [66]	Mouse; *in vitro*	Pre-treatment of mesenchymal stromal cells with asprosin significantly improved cardiac function and reduced cardiac fibrosis when implanted into infarcted mice hearts. Asprosin treatment also protected mesenchymal stromal cells from H_2O_2-induced oxidative stress and apoptosis via the SOD2-ERK1/2 pathway.
Liu *et al.* (2020) [24]	Mouse	OLFR734 is expressed in $AgRP^+$ neurons and asprosin acts via this receptor to activate these neurons and promote food intake in fasting mice. Asprosin also enhances olfactory performance via the OLFR734 receptor.
Wen *et al.* (2020) [65]	*In vitro*	Asprosin protected cardiomyoblasts from H_2O_2-induced cell death and improved mitochondrial respiration.
Rezk *et al.* (2020) [58]	Rat	Circulating asprosin levels were higher in pregnant compared to non-pregnant rats. Rats with GDM exhibited significantly elevated plasma asprosin levels compared to the healthy controls, and these levels were reduced after insulin treatment.
Zhang *et al.* (2021) [14]	Mouse; *in vitro*	Asprosin, expressed by a strain of *Pichia pastoris*, showed three glycosylation sites (threonine 8, 9 and 10) in two amino acid sequences of asprosin. Treatment of skeletal muscle cells with asprosin increased GLUT4 expression and AMPK phosphorylation, resulting in increased glucose uptake.

AgRP; agouti-related protein, AMPK; 5' adenosine monophosphate-activated protein kinase, cAMP; cyclic adenosine monophosphate, ERK; extracellular signal-regulated kinases, GABA; gamma-aminobutyric acid, GDM; gestational diabetes mellitus, GLUT4; glucose transporter type 4, H_2O_2; hydrogen peroxide, JNK; c-Jun N-terminal kinases, PKA; protein kinase A, PKCδ; protein kinase C delta, POMC; pro-opiomelanocortin, SOD2; superoxide dismutase 2, T1DM; type 1 diabetes mellitus, TGFβ; transforming growth factor beta, TLR4; toll-like receptor 4

Journal Pre-proof

Figure 1. Cleavage of pro-fibrillin to produce asprosin. Asprosin is produced together with fibrillin-1 by furin-mediated c-terminal cleavage of the pro-protein (pro-fibrillin) encoded by the *Fibrillin-1* (*FBN1*) gene (the amino acid sequence of asprosin is encoded by the last two exons of *FBN1*, *i.e.* exon 65 and 66).



Journal Pre-proof

Figure 2. Signalling pathways known to mediate the effects of asprosin. Asprosin exerts its effects by acting mainly via a G-protein coupled receptor, namely olfactory receptor OLFR734 in mice (OR4M1 is the human orthologue of OLFR734), and potentially via other receptors, such as toll-like receptor 4 (TLR4) or other unknown receptors. Akt; protein kinase B, cAMP; cyclic adenosine monophosphate, ERK; extracellular signal-regulated kinases, ER stress; endoplasmic reticulum stress, IRS-1; insulin receptor substrate-1, JNK; c-Jun N-terminal kinases, NFκB; nuclear factor kappa-light-chain-enhancer of activated B cells, PKA; protein kinase A, PKCδ; protein kinase C delta; SERCA; sarco/endoplasmic reticulum Ca2+-ATPase, SOD2; superoxide dismutase 2; ↓: decrease; ↑: increase; ?: unknown.



Figure 3. Schematic representation of the effects of asprosin in different organs/tissues/cells based on *in vitro* and *in vivo* data. AgRP^{+}: agouti-related protein expressing neurons in the hypothalamus; ER: endoplasmic reticulum; ↓: decrease; ↑: increase.

Journal Pre-proof